Skip to main content
. 2022 Jul 28;146(10):724–739. doi: 10.1161/CIRCULATIONAHA.121.057978

Figure 5.

Figure 5.

Overexpression of the LIPC-E97G variant markedly lowers LDL-C and HDL-C in APOE*3.Leiden.CETP mice. A, Experimental setup of mice study overexpressing AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G in APOE*3.Leiden.CETP mice. B, Human hepatic lipase (HL) levels as determined by ELISA in preheparin and postheparin plasma of mice overexpressing low or high doses of AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G. C and D, Triglyceride (TG) lipase activity and phospholipase A1 (PLA1) activity in plasma of APOE*3.Leiden.CETP mice overexpressing low or high doses of AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G and after heparin injection. E, Triglycerides (TG), phospholipids, and cholesterol concentrations in plasma of APOE*3.Leiden.CETP mice overexpressing low or high doses of AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G. F, Cholesterol and triglyceride (TG) concentrations in fast protein liquid chromatography (FPLC)–separated pooled plasma of APOE*3.Leiden.CETP mice overexpressing high doses of AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G. G through I, Cholesterol (CHOL) and D7-cholesterol (D7-CHOL) levels extracted from liver (G), feces (H), and plasma (I) of APOE*3.Leiden.CETP mice overexpressing high doses of AAV-TBG-eGFP, AAV-TBG-LIPC, and AAV-TBG-LIPC-E97G and injected with D7-cholesterol 3 days before death. n=5 or 6 per group. A 1-way ANOVA with Tukey correction for multiple comparisons was used for statistical analysis, with a P value cutoff at P<0.05. eGFP indicates enhanced green fluorescent protein; and LIPC, lipase C, hepatic type. *P<0.05; **P<0.01; ***P<0.001.